We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical firms have generally lauded the FDA’s efforts to advance electronic dissemination of data, according to recent industry comments posted to the agency’s “Draft Guidance for Industry on Using Electronic Means to Distribute Certain Product Information.”